Similarly, in tumor samples from patient 4513-JN, CD45+ and CD3+ cells accounted for 89.7 % and 44.2 % of the tumor tissue, respectively, with the corresponding PDT model retaining 76.1 % CD45+ cells and 40.6 % CD3+ cells ex vivo (Fig. 6C). This evidence concerns the gene PTPRC and neoplasm.